{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["3D-QSAR", "Gastric cancer", "Molecular docking", "Molecular dynamic", "Pharmacophore", "Virtual screening"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "37733194", "DateCompleted": {"Year": "2023", "Month": "11", "Day": "06"}, "DateRevised": {"Year": "2023", "Month": "11", "Day": "06"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "09", "Day": "21"}], "Language": ["eng"], "ELocationID": ["10.1007/s40199-023-00480-0"], "Journal": {"ISSN": "2008-2231", "JournalIssue": {"Volume": "31", "Issue": "2", "PubDate": {"Year": "2023", "Month": "Dec"}}, "Title": "Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences", "ISOAbbreviation": "Daru"}, "ArticleTitle": "Identifying natural products for gastric cancer treatment through pharmacophore creation, 3D QSAR, virtual screening, and molecular dynamics studies.", "Pagination": {"StartPage": "243", "EndPage": "258", "MedlinePgn": "243-258"}, "Abstract": {"AbstractText": ["Gastric cancer (GC) is known as the fourth leading cause of cancer-related death and the fifth major cancer in the world, and this is a serious threat to general health all over the world. The lack of early detection markers results in a belated diagnosis, i.e. the final stages, which could be associated with the ineffectiveness of the treatment strategies, and naturally, it leads to poor prognosis. Even though a variety of treatments have been developed, there is a trend of studying traditional medicinal plants, due to the worrying side effect of drugs available in the market.", "In this study, pharmacophore generation and 3D-QSAR model were created using 50 compounds with anti-gastric cancer activity (with IC<sub>50</sub> had been reported in the previous studies).", "Based on three of the best pharmacophoric hypotheses, virtual screening was performed to discover the top anti-gastric cancer compounds from a database of 183,885 compounds. The selected compounds were used for molecular docking with three protein receptors 7BKG, 4F5B, and 4ZT1 to investigate the intermolecular interactions between these ligands and receptors. Finally, 21 lead compounds with the highest amount of docking score ranging from -\u200913.366 to -6.404\u00a0kcal/mol were selected, and then the ADME/Tox properties of these compounds were calculated. All these compounds have a fitness score above 1.8, a molecular weight of less than 500\u00a0g/mol, hydrogen bond donors up to 3, hydrogen bond acceptors up to 8.50, and logP of 1.013 to 4.174. Finally, molecular dynamic simulations for top-scoring ligand-receptor complexes were investigated.", "These selected lead compounds have the most anti-gastric cancer effects among the 183,885 compounds in the database. Therefore, lead compounds might be considered for gastric cancer therapy in future studies."], "CopyrightInformation": "\u00a9 2023. The Author(s), under exclusive licence to Tehran University of Medical Sciences."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Phytochemistry, Medicinal Plants and Drugs Research Institute, Shahid Beheshti University, Evin, 1983963113, Tehran, Iran."}], "LastName": "Jalali", "ForeName": "Zeinab", "Initials": "Z"}, {"Identifier": ["0000-0003-2167-8032"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Phytochemistry, Medicinal Plants and Drugs Research Institute, Shahid Beheshti University, Evin, 1983963113, Tehran, Iran. s_ebrahimi@sbu.ac.ir."}], "LastName": "Nejad Ebrahimi", "ForeName": "Samad", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Phytochemistry, Medicinal Plants and Drugs Research Institute, Shahid Beheshti University, Evin, 1983963113, Tehran, Iran."}], "LastName": "Rezadoost", "ForeName": "Hassan", "Initials": "H"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Daru", "NlmUniqueID": "101125969", "ISSNLinking": "1560-8115"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Biological Products"}, {"RegistryNumber": "0", "NameOfSubstance": "Ligands"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Molecular Dynamics Simulation"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": [], "DescriptorName": "Quantitative Structure-Activity Relationship"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Stomach Neoplasms"}, {"QualifierName": [], "DescriptorName": "Pharmacophore"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Biological Products"}, {"QualifierName": [], "DescriptorName": "Early Detection of Cancer"}, {"QualifierName": [], "DescriptorName": "Ligands"}], "CoiStatement": "The authors did not have any conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68(6):394\u2013424. doi: 10.3322/caac.21492.", "ArticleIdList": ["10.3322/caac.21492", "30207593"]}, {"Citation": "Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pi\u00f1eros M, Znaor A, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;149(4):778\u2013789. doi: 10.1002/ijc.33588.", "ArticleIdList": ["10.1002/ijc.33588", "33818764"]}, {"Citation": "Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209\u2013249. doi: 10.3322/caac.21660.", "ArticleIdList": ["10.3322/caac.21660", "33538338"]}, {"Citation": "Zaafouri H, Jouini R, Khedhiri N, Khanchel F, Cherif M, Mesbahi M, et al. Comparison between signet-ring cell carcinoma and non-signet-ring cell carcinoma of the stomach: clinicopathological parameters, epidemiological data, outcome, and prognosis\u2014a cohort study of 123 patients from a non-endemic country. World J Surg Oncol. 2022;20(1):1\u201312. doi: 10.1186/s12957-022-02699-8.", "ArticleIdList": ["10.1186/s12957-022-02699-8", "PMC9297662", "35858903"]}, {"Citation": "Liu D, Zhang R, Chen S, Sun B, Zhang K. Analysis of gastric microbiome reveals three distinctive microbial communities associated with the occurrence of gastric cancer. BMC Microbiol. 2022;22(1):1\u201313. doi: 10.1186/s12866-022-02594-y.", "ArticleIdList": ["10.1186/s12866-022-02594-y", "PMC9308235", "35870901"]}, {"Citation": "Jiang X-j, Lin J, Cai Q-h, Zhao J-f, Zhang H-j. CDH17 alters MMP-2 expression via canonical NF-\u03baB signalling in human gastric cancer. Gene. 2019;682:92\u2013100. doi: 10.1016/j.gene.2018.05.042.", "ArticleIdList": ["10.1016/j.gene.2018.05.042", "29783070"]}, {"Citation": "Yang Y, Chen Y, Hu Y, Feng Y, Mao Q, Xue W. Outcomes of laparoscopic versus open total gastrectomy with D2 lymphadenectomy for gastric cancer: a systematic review and meta-analysis. Eur J Med Res. 2022;27(1):1\u20139. doi: 10.1186/s40001-022-00748-2.", "ArticleIdList": ["10.1186/s40001-022-00748-2", "PMC9290297", "35844000"]}, {"Citation": "Shi J, Li N, Tang Y, Jiang L, Yang L, Wang S, et al. Total neoadjuvant therapy for locally advanced gastric cancer and esophagogastric junction adenocarcinoma: study protocol for a prospective, multicenter, single-arm, phase II clinical trial. BMC Gastroenterol. 2022;22(1):1\u20139. doi: 10.1186/s12876-022-02440-5.", "ArticleIdList": ["10.1186/s12876-022-02440-5", "PMC9331588", "35902798"]}, {"Citation": "Lee HJ, Venkatarame Gowda Saralamma V, Kim SM, Ha SE, Vetrivel P, Kim EH, et al. Comparative proteomic profiling of tumor-associated proteins in human gastric cancer cells treated with pectolinarigenin. Nutrients. 2018;10(11):1596. doi: 10.3390/nu10111596.", "ArticleIdList": ["10.3390/nu10111596", "PMC6265996", "30380781"]}, {"Citation": "Wang X, Zhi Q, Liu S, Xue S-L, Shen C, Li Y, et al. Identification of specific biomarkers for gastric adenocarcinoma by ITRAQ proteomic approach. Sci Rep. 2016;6(1):1\u201315.", "ArticleIdList": ["PMC5150883", "27941907"]}, {"Citation": "Zhu AK, Shan YQ, Zhang J, Liu XC, Ying RC, Kong WC. Exosomal NNMT from peritoneum lavage fluid promotes peritoneal metastasis in gastric cancer. Kaohsiung J Med Sci. 2021;37(4):305\u2013313. doi: 10.1002/kjm2.12334.", "ArticleIdList": ["10.1002/kjm2.12334", "33508890"]}, {"Citation": "Chen Y, Ye B, Wang C, Nie Y, Qin J, Shen Z. PLOD3 contributes to HER-2 therapy resistance in gastric cancer through FoxO3/Survivin pathway. Cell Death Discovery. 2022;8(1):1\u201312. doi: 10.1038/s41420-022-01103-4.", "ArticleIdList": ["10.1038/s41420-022-01103-4", "PMC9283410", "35835735"]}, {"Citation": "Zhao S, Bi Y, Wang Z, Zhang F, Zhang Y, Xu Y. Accuracy evaluation of combining gastroscopy, multi-slice spiral CT, Her-2, and tumor markers in gastric cancer staging diagnosis. World J Surg Oncol. 2022;20(1):1\u201310. doi: 10.1186/s12957-022-02616-z.", "ArticleIdList": ["10.1186/s12957-022-02616-z", "PMC9092869", "35545785"]}, {"Citation": "Lordick F, Kang Y-K, Chung H-C, Salman P, Oh SC, Bodoky G, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14(6):490\u2013499. doi: 10.1016/S1470-2045(13)70102-5.", "ArticleIdList": ["10.1016/S1470-2045(13)70102-5", "23594786"]}, {"Citation": "Wang Y, Yin X, Chen L, Yin Z, Zuo Z. Discovery and evaluation of cytisine N-isoflavones as novel EGFR/HER2 dual inhibitors. Bioorg Chem. 2022;127:105868. doi: 10.1016/j.bioorg.2022.105868.", "ArticleIdList": ["10.1016/j.bioorg.2022.105868", "35816874"]}, {"Citation": "Xu S, Chen W, Wang Y, Zhang Y, Xia R, Shen J, et al. N6-methyladenosine-related lncRNAs identified as potential biomarkers for predicting the overall survival of asian gastric cancer patients. BMC Cancer. 2022;22(1):1\u201318. doi: 10.1186/s12885-022-09801-z.", "ArticleIdList": ["10.1186/s12885-022-09801-z", "PMC9248105", "35778697"]}, {"Citation": "Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29(30):3968\u20133976. doi: 10.1200/JCO.2011.36.2236.", "ArticleIdList": ["10.1200/JCO.2011.36.2236", "21844504"]}, {"Citation": "Chu X-d, Lin Z-b, Huang T, Ding H, Zhang Y-r, Zhao Z, et al. Thrombospondin-2 holds prognostic value and is associated with metastasis and the mismatch repair process in gastric cancer. BMC Cancer. 2022;22(1):1\u201313. doi: 10.1186/s12885-022-09201-3.", "ArticleIdList": ["10.1186/s12885-022-09201-3", "PMC8900425", "35255858"]}, {"Citation": "Iveson T, Donehower RC, Davidenko I, Tjulandin S, Deptala A, Harrison M, et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Lancet Oncol. 2014;15(9):1007\u20131018. doi: 10.1016/S1470-2045(14)70023-3.", "ArticleIdList": ["10.1016/S1470-2045(14)70023-3", "24965569"]}, {"Citation": "Anestis A, Zoi I, Karamouzis MV. Current advances of targeting HGF/c-Met pathway in gastric cancer. Ann Transl Med. 2018;6(12):247.", "ArticleIdList": ["PMC6046293", "30069449"]}, {"Citation": "Yuan J, Tan L, Yin Z, Tao K, Wang G, Shi W, et al. Glis2 redundancy causes chemoresistance and poor prognosis of gastric cancer based on co\u2013expression network analysis. Oncol Rep. 2019;41(1):191\u2013201.", "ArticleIdList": ["PMC6278374", "30320360"]}, {"Citation": "Kim HK, Reyzer ML, Choi IJ, Kim CG, Kim HS, Oshima A, et al. Gastric cancer-specific protein profile identified using endoscopic biopsy samples via MALDI mass spectrometry. J Proteome Res. 2010;9(8):4123\u20134130. doi: 10.1021/pr100302b.", "ArticleIdList": ["10.1021/pr100302b", "PMC3441055", "20557134"]}, {"Citation": "Wang L, Chen J, Zuo Q, Wu C, Yu T, Zheng P, et al. Calreticulin enhances gastric cancer metastasis by dimethylating H3K9 in the E-cadherin promoter region mediating by G9a. Oncogenesis. 2022;11(1):1\u201311. doi: 10.1038/s41389-022-00405-7.", "ArticleIdList": ["10.1038/s41389-022-00405-7", "PMC9156786", "35641480"]}, {"Citation": "Zhang L, Song M, Zhang F, Yuan H, Chang W, Yu G, et al. Accumulation of nicotinamide N-methyltransferase (NNMT) in cancer-associated fibroblasts: a potential prognostic and predictive biomarker for gastric carcinoma. J Histochem Cytochem. 2021;69(3):165\u2013176. doi: 10.1369/0022155420976590.", "ArticleIdList": ["10.1369/0022155420976590", "PMC7905490", "33283625"]}, {"Citation": "Pozzi V, Campagna R, Sartini D, Emanuelli M. Nicotinamide N-methyltransferase as promising tool for management of gastrointestinal neoplasms. Biomolecules. 2022;12(9):1173. doi: 10.3390/biom12091173.", "ArticleIdList": ["10.3390/biom12091173", "PMC9496617", "36139012"]}, {"Citation": "Okamoto W, Okamoto I, Yoshida T, Okamoto K, Takezawa K, Hatashita E, et al. Identification of c-Src as a potential therapeutic target for gastric Cancer and of MET activation as a cause of resistance to c-Src inhibitionc-src as a therapeutic target for gastric Cancer. Mol Cancer Ther. 2010;9(5):1188\u20131197. doi: 10.1158/1535-7163.MCT-10-0002.", "ArticleIdList": ["10.1158/1535-7163.MCT-10-0002", "20406949"]}, {"Citation": "Nam H-J, Im S-A, Oh D-Y, Elvin P, Kim H-P, Yoon Y-K, et al. Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancerantitumor effects of saracatinib in gastric Cancer. Mol Cancer Ther. 2013;12(1):16\u201326. doi: 10.1158/1535-7163.MCT-12-0109.", "ArticleIdList": ["10.1158/1535-7163.MCT-12-0109", "23144237"]}, {"Citation": "Malpeli G, Barbi S, Innamorati G, Alloggio M, Filippini F, Decimo I, et al. Landscape of druggable molecular pathways downstream of genomic CDH1/Cadherin-1 alterations in gastric Cancer. J Personalized Med. 2022;12(12):2006. doi: 10.3390/jpm12122006.", "ArticleIdList": ["10.3390/jpm12122006", "PMC9784514", "36556227"]}, {"Citation": "Yan Q, Wu Y, Li D, Li Y. A-Kinase anchoring protein 9 promotes gastric cancer progression as a downstream effector of cadherin 1. J Oncology 2022:2830634.", "ArticleIdList": ["PMC9617730", "36317124"]}, {"Citation": "Wanga X-z, Gu J-l, Gao M, Bian Y, Liang J-y, Wen H-m, et al. Peperomin E induces promoter hypomethylation of metastatic-suppressor genes and attenuates metastasis in poorly differentiated gastric Cancer. Cell Physiol. 2018;50(6):2341\u20132364.", "ArticleIdList": ["30423554"]}, {"Citation": "Ngabire D, Seong Y, Patil MP, Niyonizigiye I, Seo YB, Kim G-D. Induction of apoptosis and G1 phase cell cycle arrest by Aster incisus in AGS gastric adenocarcinoma cells. Int J Oncol. 2018;53(5):2300\u20132308.", "ArticleIdList": ["30226597"]}, {"Citation": "Trinh TA, Lee D, Park S, Kim SH, Park JG, Kim JH, et al. Stilbenes contribute to the anticancer effects of Rheum undulatum L. through activation of apoptosis. Oncol Lett. 2019;17(3):2953\u20132959.", "ArticleIdList": ["PMC6365963", "30854073"]}, {"Citation": "Shukla S, Mehta A. Anticancer potential of medicinal plants and their phytochemicals: a review. Brazilian J Bot. 2015;38(2):199\u2013210. doi: 10.1007/s40415-015-0135-0.", "ArticleIdList": ["10.1007/s40415-015-0135-0"]}, {"Citation": "Ashktorab H, Soleimani A, Singh G, Amin A, Tabtabaei S, Latella G, et al. Saffron: the golden spice with therapeutic properties on digestive diseases. Nutr Cancer. 2019;11(5):943.", "ArticleIdList": ["PMC6567082", "31027364"]}, {"Citation": "Alibeiki F, Jafari N, Karimi M, Peeri Dogaheh H. Potent anti-cancer effects of less polar curcumin analogues on gastric adenocarcinoma and esophageal squamous cell carcinoma cells. Sci Rep. 2017;7(1):1\u20139. doi: 10.1038/s41598-017-02666-4.", "ArticleIdList": ["10.1038/s41598-017-02666-4", "PMC5451386", "28566729"]}, {"Citation": "Ham I-H, Wang L, Lee D, Woo J, Kim TH, Jeong HY, et al. Curcumin inhibits the cancer\u2013associated fibroblast\u2013derived chemoresistance of gastric cancer through the suppression of the JAK/STAT3 signaling pathway. Int J Oncol. 2022;61(1):1\u201312. doi: 10.3892/ijo.2022.5375.", "ArticleIdList": ["10.3892/ijo.2022.5375", "PMC9170354", "35621145"]}, {"Citation": "Mohammadi A, Khanbabaei H, Zandi F, Ahmadi A, Haftcheshmeh SM, Johnston TP et al. Curcumin: a therapeutic strategy for targeting the Helicobacter pylori-related diseases. Microb Pathog. 2022:105552.", "ArticleIdList": ["35469998"]}, {"Citation": "Shang HS, Lu HF, Lee CH, Chiang HS, Chu YL, Chen A, et al. Quercetin induced cell apoptosis and altered gene expression in AGS human gastric cancer cells. Environ Toxicol. 2018;33(11):1168\u20131181. doi: 10.1002/tox.22623.", "ArticleIdList": ["10.1002/tox.22623", "30152185"]}, {"Citation": "Sathianarayanan S, Aparna V, Biswas R, Anita B, Sukumaran S, Venkidasamy B. A new approach against Helicobacter pylori using plants and its constituents: a review study. Microb Pathog. 2022:168:105594.", "ArticleIdList": ["35605740"]}, {"Citation": "Zhang Q, Wang X, Cao S, Sun Y, He X, Jiang B, et al. Berberine represses human gastric cancer cell growth in vitro and in vivo by inducing cytostatic autophagy via inhibition of MAPK/mTOR/p70S6K and akt signaling pathways. Biomed Pharmacother. 2020;128:110245. doi: 10.1016/j.biopha.2020.110245.", "ArticleIdList": ["10.1016/j.biopha.2020.110245", "32454290"]}, {"Citation": "Li L-L, Peng Z, Hu Q, Xu L-J, Zou X, Huang D-M, et al. Berberine retarded the growth of gastric cancer xenograft tumors by targeting hepatocyte nuclear factor 4\u03b1. World J Gastrointest Oncol. 2022;14(4):842. doi: 10.4251/wjgo.v14.i4.842.", "ArticleIdList": ["10.4251/wjgo.v14.i4.842", "PMC9048536", "35582103"]}, {"Citation": "Tsai C-L, Chiu Y-M, Ho T-Y, Hsieh C-T, Shieh D-C, Lee Y-J, et al. Gallic acid induces apoptosis in human gastric adenocarcinoma cells. Anticancer Res. 2018;38(4):2057\u20132067.", "ArticleIdList": ["29599323"]}, {"Citation": "Kim S, Kim W, Kim D-H, Jang J-H, Kim S-J, Park S-A, et al. Resveratrol suppresses gastric cancer cell proliferation and survival through inhibition of PIM-1 kinase activity. Arch Biochem. 2020;689:108413. doi: 10.1016/j.abb.2020.108413.", "ArticleIdList": ["10.1016/j.abb.2020.108413", "32473133"]}, {"Citation": "Wang L-Y, Zhao S, Lv G-J, Ma X-J, Zhang J-B. Mechanisms of resveratrol in the prevention and treatment of gastrointestinal cancer. World J Clin Cases. 2020;8(12):2425. doi: 10.12998/wjcc.v8.i12.2425.", "ArticleIdList": ["10.12998/wjcc.v8.i12.2425", "PMC7322414", "32607320"]}, {"Citation": "Qi Z, Tang T, Sheng L, Ma Y, Liu Y, Yan L, et al. Salidroside inhibits the proliferation and migration of gastric cancer cells via suppression of src\u2013associated signaling pathway activation and heat shock protein 70 expression. Mol Med Rep. 2018;18(1):147\u2013156.", "ArticleIdList": ["PMC6059663", "29749547"]}, {"Citation": "Ayeleso TB, Matumba MG, Mukwevho E. Oleanolic acid and its derivatives: biological activities and therapeutic potential in chronic diseases. Molecules. 2017;22(11):1915. doi: 10.3390/molecules22111915.", "ArticleIdList": ["10.3390/molecules22111915", "PMC6150249", "29137205"]}, {"Citation": "Li Y, Xu Q, Yang W, Wu T, Lu X. Oleanolic acid reduces aerobic glycolysis-associated proliferation by inhibiting yes-associated protein in gastric cancer cells. Gene. 2019;712:143956. doi: 10.1016/j.gene.2019.143956.", "ArticleIdList": ["10.1016/j.gene.2019.143956", "31271843"]}, {"Citation": "Atnip A, Giusti MM, Sigurdson GT, Failla ML, Chitchumroonchokchai C, Bomser JA, et al. The NCI-N87 Cell line as a gastric epithelial model to study cellular uptake, trans-epithelial transport, and gastric anti-inflammatory properties of anthocyanins. Nutr Cancer. 2020;72(4):686\u201395. doi: 10.1080/01635581.2019.1644354.", "ArticleIdList": ["10.1080/01635581.2019.1644354", "31353956"]}, {"Citation": "Mathur S, Pareek S, Verma R, Shrivastava D, Bisen PS. Therapeutic potential of ginger bio-active compounds in gastrointestinal cancer therapy: the molecular mechanism. Nutrire. 2022;47(2):1\u201317."}, {"Citation": "Singh MP, Chawla V, Kaushik D, Chawla PA, Sisodia SS. Pharmacodynamic stance of phytoconstituents as a gastric Ulcer Protective mechanism: an overview. Curr Mol Med. 2022;22(5):431\u2013441. doi: 10.2174/1566524021666210806161835.", "ArticleIdList": ["10.2174/1566524021666210806161835", "34365948"]}, {"Citation": "Bhansali SG, Kulkarni VM. Pharmacophore generation, atom-based 3D-QSAR, docking, and virtual screening studies of p38-\u03b1 mitogen activated protein kinase inhibitors: pyridopyridazin-6-ones (part 2) Res Rep Med Chem. 2014;4:1."}, {"Citation": "Consonni V, Ballabio D, Todeschini R. Comments on the definition of the Q 2 parameter for QSAR validation. J Chem Inf Model. 2009;49(7):1669\u20131678. doi: 10.1021/ci900115y.", "ArticleIdList": ["10.1021/ci900115y", "19527034"]}, {"Citation": "Dixon SL, Smondyrev AM, Knoll EH, Rao SN, Shaw DE, Friesner RA. PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aided Mol Des. 2006;20(10):647\u2013671. doi: 10.1007/s10822-006-9087-6.", "ArticleIdList": ["10.1007/s10822-006-9087-6", "17124629"]}, {"Citation": "Abbasi M, Sadeghi-Aliabadi H, Amanlou M. Prediction of new Hsp90 inhibitors based on 3, 4-isoxazolediamide scaffold using QSAR study, molecular docking and molecular dynamic simulation. DARU J Pharm Sci. 2017;25:1\u201316. doi: 10.1186/s40199-017-0182-0.", "ArticleIdList": ["10.1186/s40199-017-0182-0", "PMC5493083", "28666484"]}, {"Citation": "Alam S, Khan F. 3D-QSAR, docking, ADME/Tox studies on Flavone analogs reveal anticancer activity through tankyrase inhibition. Sci Rep. 2019;9(1):1\u201315. doi: 10.1038/s41598-019-41984-7.", "ArticleIdList": ["10.1038/s41598-019-41984-7", "PMC6443786", "30932078"]}, {"Citation": "Zolghadr L, Behbehani GR, PakBin B, Hosseini SA, Divsalar A, Gheibi N. Molecular dynamics simulations, molecular docking, and kinetics study of kaempferol interaction on Jack bean urease: comparison of extended solvation model. Food Sci Nutr. 2022;10(11):3585\u20133597. doi: 10.1002/fsn3.2956.", "ArticleIdList": ["10.1002/fsn3.2956", "PMC9632207", "36348777"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "5", "Day": "24"}, {"Year": "2023", "Month": "9", "Day": "6"}, {"Year": "2024", "Month": "9", "Day": "21"}, {"Year": "2023", "Month": "11", "Day": "6", "Hour": "6", "Minute": "41"}, {"Year": "2023", "Month": "9", "Day": "21", "Hour": "12", "Minute": "42"}, {"Year": "2023", "Month": "9", "Day": "21", "Hour": "11", "Minute": "13"}], "PublicationStatus": "ppublish", "ArticleIdList": ["37733194", "PMC10624797", "10.1007/s40199-023-00480-0", "10.1007/s40199-023-00480-0"]}}], "PubmedBookArticle": []}